|
Sep 25
|
With 65% ownership, Cerus Corporation (NASDAQ:CERS) boasts of strong institutional backing
|
|
Jun 21
|
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
|
|
Jun 16
|
Cerus (NASDAQ:CERS) shareholders have endured a 70% loss from investing in the stock three years ago
|
|
Jun 14
|
Cerus Corporation Celebrates World Blood Donor Day 2024
|
|
May 22
|
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
|
|
May 4
|
Cerus First Quarter 2024 Earnings: EPS Misses Expectations
|
|
May 3
|
Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Q1 2024 Cerus Corp Earnings Call
|
|
May 3
|
Cerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
|
|
May 2
|
Cerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows
|
|
May 2
|
Cerus Corporation Announces First Quarter 2024 Financial Results
|
|
Apr 18
|
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
|
|
Apr 18
|
Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%
|
|
Mar 26
|
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
|
|
Mar 19
|
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
|
|
Mar 15
|
Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
|
|
Mar 15
|
Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
|
|
Mar 8
|
Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
|
|
Mar 7
|
Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
|
|
Mar 7
|
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
|